MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issue of
ordinary shares
$15K
Net cash provided by
financing activities
$15K
(decrease)/increase in cash and cash
equivalents
-$110,248K
Canceled cashflow
$15K
Net foreign
exchange impacts
-$11,022K
Share-based compensation
expense
$8,074K
Decrease/(increase) in other current
assets
-$6,016K
Decrease/(increase) in r&d benefit
receivable
-$4,041K
Decrease in other
long-term assets
-$3,658K
Decrease/(increase) in trade
receivables
-$1,024K
Depreciation expense
$312K
Amortization expense
$243K
Income tax expense
$11K
Redemption of term deposits
$118,476K
Net cash used in
operating activities
-$62,271K
Net cash used in
investing activities
-$47,992K
Canceled cashflow
$34,401K
Canceled cashflow
$118,476K
Net loss after tax
-$88,612K
Purchase of term deposits
$166,413K
(decrease)/increase in trade and
other payables
-$4,078K
Other income, net
$3,480K
Decrease in contract
liabilities
-$334K
Decrease in operating
lease liabilities
-$168K
Purchase of property,
plant and equipment
$55K
Back
Back
Cash Flow
source: myfinsight.com
Silence Therapeutics plc (SLN)
Silence Therapeutics plc (SLN)